Edition:
United Kingdom

Corbus Pharma reports improvement in skin conditions in a mid-stage study


Monday, 6 Nov 2017 

Nov 6 (Reuters) - Corbus Pharmaceuticals Holdings Inc :Corbus Pharmaceuticals reports significant improvement in mRSS and other clinical outcomes at 28-weeks in systemic sclerosis open-label extension of phase 2 study.Corbus Pharmaceuticals Holdings Inc - ‍Company on track to commence phase 3 study Q4 2017​.Corbus Pharmaceuticals Holdings Inc - Were no severe or serious adverse events and no clinically significant laboratory abnormalities related to drug​.Corbus Pharmaceuticals - "‍Our focus now is to ensure successful execution of our phase 3 study, and we are on track to commence this before year end"​.